middle.news
Percheron Licenses Phase II-Ready Cancer Drug, Plans 2026 Trials
8:40am on Thursday 31st of July, 2025 AEST
•
Biotechnology
Read Story
Percheron Licenses Phase II-Ready Cancer Drug, Plans 2026 Trials
8:40am on Thursday 31st of July, 2025 AEST
Key Points
Exclusive worldwide license for HMBD-002 from Hummingbird Bioscience
HMBD-002 completed phase I trial with strong safety profile
FDA IND sponsorship transferred to Percheron enabling clinical trial initiation
Phase II clinical trial planned for 2026 with ongoing expert consultations
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Percheron Therapeutics (ASX:PER)
OPEN ARTICLE